Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Up 3.6% – Should You Buy?

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were up 3.6% on Wednesday. The stock traded as high as $779.67 and last traded at $780.4880. Approximately 375,131 shares were traded during trading, a decline of 54% from the average daily volume of 819,843 shares. The stock had previously closed at $753.12.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EU regulators recommended approval of an updated Libtayo dosing schedule. The CHMP opinion would allow cemiplimab to be administered every six weeks, rather than every three weeks, after the first 12 weeks across all approved cancer types. The less-frequent regimen could improve patient convenience and support Libtayo’s commercial profile, although final European Commission approval is still required. Libtayo CHMP recommendation
• Positive Sentiment: Encouraging 84-week Phase III data for Regeneron’s FOP treatment gave investors another sign of pipeline progress and potentially durable efficacy in a rare-disease indication. Regeneron FOP trial update
• Positive Sentiment: UBS upgraded REGN to “Buy” and raised its price target to $978 from $660. UBS believes the market is underestimating the long-term opportunity for Dupixent, adding a significant bullish valuation signal. UBS Regeneron upgrade
• Positive Sentiment: Regeneron’s latest reported quarter showed $4.29 billion in revenue, up 16.7% year over year, and EPS of $14.29 versus a $10.16 consensus estimate. Analysts also expect double-digit bottom-line growth in the upcoming third-quarter report, reinforcing the earnings-momentum narrative. Regeneron earnings and valuation report Regeneron earnings preview
• Positive Sentiment: Analysts continue to describe REGN as undervalued, citing fresh trial data, its immunology alliance and the potential benefit of having paid off its balance owed to Sanofi. Regeneron fair value analysis Regeneron growth catalysts
• Negative Sentiment: Insider Andrew Murphy sold 4,147 shares worth approximately $3.2 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, limiting its significance, but it remains a modest potential headwind for sentiment. SEC insider transaction filing

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent analyst reports. The Goldman Sachs Group boosted their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Citigroup boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $845.21.

Regeneron Pharmaceuticals Stock Up 2.3%

The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm’s 50 day moving average price is $791.59 and its two-hundred day moving average price is $721.30. The firm has a market cap of $81.99 billion, a price-to-earnings ratio of 19.68, a P/E/G ratio of 1.35 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. This represents a 8.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock valued at $6,506,845 in the last ninety days. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $5,682,636,000. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 7.2% during the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after acquiring an additional 106,632 shares during the last quarter. Bank of America Corp DE increased its position in Regeneron Pharmaceuticals by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after purchasing an additional 101,469 shares in the last quarter. Finally, Amundi increased its position in Regeneron Pharmaceuticals by 0.4% during the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after purchasing an additional 3,742 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.